Second‐generation antipsychotic drugs for obsessive compulsive disorder
References
Additional references
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic‐induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry 1999;156(11):1686‐96.
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III). Washington DC: American Psychiatric Association, 1980.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition‐ Revised (DSM‐III‐R). Washington, DC: American Psychiatric Association, 1987.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM‐IV). Washington DC: American Psychiatric Association, 1994.
Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63‐101.
Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Bloch MH, Landeros‐Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive compulsive disorder. Molecular Psychiatry 2006;11:622‐32.
Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire H, Barbui C. Paroxetine versus other anti‐depressive agents for depression. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006531]
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of one‐year studies. American Journal of Psychiatry 2004;161:414‐5.
Der‐Simonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88.
Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9.
Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31:140‐9.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analysis can provide accurate results. Journal of Clinical Epidemiology 2006;59:7‐10.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale ‐Brown Obsessive Compulsive Scale: Development, use and reliability. Archives of General Psychiatry 1989;46(11):1012‐6.
Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O´Keane V, Papakostas G, Vieta E, Zohar J. Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus Meeting, March 2008, Nice. European Neuropsychopharmacology 2009;19:520‐32.
Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Guy W. Clinical Global Impressions ‐ ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76‐338). Revised. Rockville MD: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH, 1976.
Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50‐5.
Hawkridge S, Ipser JC, Stein DJ. Pharmacotherapy for anxiety disorder in children and adolescents. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005170.pub2]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org2008.
Maia TV, Cooney RE, Petersen BS. The neural base of obsessive compulsive disorder in children and adults. Development and psychopathology 2008;20:1251‐83.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382‐9.
Pallanti S, Quercioli L. Treatment‐refractory obsessive‐compulsive disorder: methodological issues, operational definitions and therapeutic lines. Progress in Neuropsychopharmacology and Biological Psychiatry 2006;30(3):400‐12.
Ravindran AV, Bradbury C, McKay M, da Silva TL. Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. Expert Opinion in Pharmacotherapy 2007;8(11):1693‐710.
Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive‐compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry 2008;epub ahead of print:no page numbers available.
Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Current Psychiatry Reports 2003;5(4):320‐6.
Vital Signs. Seroquel led antipsychotics sales in 2006. Clinical Psychiatric News 2007;35:1.
World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD‐10). Geneva: World Health Organisation, 1992.
Zaudig M, Hauke W, Hegerl U. Epidemiology, comorbidity and course of obsessive compulsive disorder [Epidemilogie, Komorbidität und Verlauf der Zwangsstörung [German]]. In: Michael Zaudig, Sabine Bosser‐Zaudig editor(s). Obsessive Compulsive Disorder: Diagnosis and Treatment [Die Zwangsstörung: Diagnostik und Therapie]. Stuttgart: Schattauer, 2002. [ISBN: 3794521455]
